ArticleBMC women's health2026
Preoperative pan-immune-inflammation value and geriatric nutritional risk index predict outcomes of elderly patients with endometrial carcinoma after radical surgery.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundTo evaluate the prognostic value of preoperative geriatric nutritional risk index (GNRI) and pan-immune-inflammation value (PIV), individually and in combination, for overall survival (OS), recurrence-free survival (RFS), and two-year recurrence rates in this specific population. MATERIALS AND
methodsGNRI and PIV were calculated from preoperative laboratory data. Optimal cutoffs were determined by ROC analysis for 3-year OS. The associations with clinicopathological features and survival outcomes (OS, RFS, 2-year recurrence) were assessed. Independent prognostic factors were identified using multivariate Cox regression. The prognostic performance of the combined GNRI - PIV model was evaluated using time-dependent ROC analysis.
resultsLow GNRI (< 97.8) and high PIV (≥ 292.3) were significantly associated with advanced FIGO stage, higher tumor grade, lymph node metastasis, and increased two-year recurrence rates (all P < 0.05). Multivariate analysis confirmed both low GNRI (OS: 95% CI: 1.58–3.70, HR = 2.42, P < 0.001; RFS: 95% CI: 1.43–3.24, HR = 2.15,P < 0.001) and high PIV (OS: 95% CI: 1.43–3.32, HR = 2.18, P < 0.001; RFS: 95% CI: 1.30–2.90, HR = 1.94, P = 0.001) as independent predictors of poorer survival. The combination of GNRI and PIV demonstrated superior prognostic performance for 3-year OS (AUC = 0.81) and RFS (AUC = 0.78) compared to either marker alone. Patients with low GNRI/high PIV had the worst 2-year recurrence rate (65.8%), while those with high GNRI/low PIV and high GNRI/high PIV had significantly lower rates (9.6% and 3.1%, respectively) and superior OS and RFS compared to other groups (P < 0.001).
conclusionsLow GNRI (< 97.8) and high PIV (≥ 292.3) were significantly associated with advanced FIGO stage, higher tumor grade, lymph node metastasis, and increased two-year recurrence rates. Preoperative GNRI and PIV are potent, cost-effective, and independent prognostic biomarkers in elderly EC patients undergoing radical surgery. Their combination provides superior risk stratification for OS, RFS, and early recurrence, potentially guiding personalized adjuvant treatment and follow-up strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.